Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 2, 2007, Pages 417-422

  Lodise, Thomas P ^a,b   Miller, Christopher D ^a,c   Graves, Jeffrey ^a   Furuno, Jon P ^d   McGregor, Jessina C ^d   Lomaestro, Ben ^e   Graffunder, Eileen ^e   McNutt, Louise Anne ^f  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CLASSIFICATION AND REGRESSION TREE ANALYSIS; DRUG EXPOSURE; FEMALE; HIGH RISK POPULATION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 33846606770     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00851-06     Document Type: Article

References (36)

1. Aloush, V., S. Navon-Venezia, Y. Seigman-Igra, S. Cabili, and Y. Carmeli. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
2. Anonymous. 1999. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: a report from the National Nosocomial Infections Surveillance (NNIS) system. Am. J. Infect. Control 27:279-284.
3. Arruda, E. A., I. S. Marinho, M. Boulos, S. I. Sinto, H. H. Caiaffa, C. M. Mendes, C. P. Oplustil, H. Sader, C. E. Levy, and A. S. Levin. 1999. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 20:620-623.
4. Cao, B., H. Wang, H. Sun, Y. Zhu, and M. Chen. 2004. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect. 57:112-118.
5. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
6. Clinical and Laboratory Standards Institute. 2006. M2-M9 - performance standards for antimicrobial disk susceptibility tests; approved standards - ninth edition. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Criteria Committee of the New York Heart Association, Inc. 1973. Diagnosis of the heart and blood vessels: nomenclature and criteria for diagnosis, 7th edition. Little, Brown, Boston, MA.
8. D'Agata, E. M., M. A. Cataldo, R. Cauda, and E. Tacconelli. 2006. The importance of addressing multidrug resistance and not assuming single-drug resistance in case-control studies. Infect. Control Hosp. Epidemiol. 27:670-674.
9. El Amari, E. B., E. Chamot, R. Auckenthaler, J. C. Pechere, and C. Van Delden. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864.
10. Falagas, M. E., and P. Kopterides. 2006. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J. Hosp. Infect. 64:7-15.
11. Friedland, I., G. Gallagher, T. King, and G. L. Woods. 2004. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter intensive care unit surveillance study (ISS) in the United States. J. Chemother. 16:437-441.
12. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16:128-140.
13. Gasink, L. B., N. O. Fishman, M. G. Weiner, I. Nachamkin, W. B. Bilker, and E. Lautenbach. 2006. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med. 119:526.e19-526.e25.
14. Harris, A., C. Torres-Viera, L. Venkataraman, P. DeGirolami, M. Samore, and Y. Carmeli. 1999. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis. 28:1128-1133.
15. Harris, A. D., Y. Carmeli, M. H. Samore, K. S. Kaye, and E. Perencevich. 2005. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infect. Control Hosp. Epidemiol. 26:342-345.
16. Harris, A. D., M. H. Samore, M. Lipsitch, K. S. Kaye, E. Perencevich, and Y. Carmeli. 2002. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin. Infect. Dis. 34:1558-1563.
17. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
18. Jones, R. N., J. T. Kirby, M. L. Beach, D. J. Biedenbach, and M. A. Pfaller. 2002. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY antimicrobial surveillance program (1997-2000). Diagn. Microbiol. Infect. Dis. 43:239-243.
19. Kang, C. I., S. H. Kim, H. B. Kim, S. W. Park, Y. J. Choe, M. D. Oh, E. C. Kim, and K. W. Choe. 2003. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis. 37:745-751.
20. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688.
21. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
22. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
23. Leibovici, L., I. Shraga, M. Drucker, H. Konigsberger, Z. Samra, and S. D. Pitlik. 1998. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med. 244:379-386.
24. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
25. Lodise, T. P., Jr., P. S. McKinnon, and M. Rybak. 2003. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect. Control Hosp. Epidemiol. 24:655-661.
26. Lodise, T. P., P. S. McKinnon, L. Swiderski, and M. J. Rybak. 2003. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. 36:1418-1423.
27. MacArthur, R. D., M. Miller, T. Albertson, E. Panacek, D. Johnson, L. Teoh, and W. Barchuk. 2004. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin. Infect. Dis. 38:284-288.
28. Margolis, D. J. 1995. Definition of a pressure ulcer. Adv. Wound Care 8:(Suppl. 4)8-10.
29. McNutt, L. A., C. Wu, X. Xue, and J. P. Hafner. 2003. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am. J. Epidemiol. 157:940-943.
30. Obritsch, M. D., D. N. Fish, R. MacLaren, R. Jung, I. Friedland, G. Gallagher, T. King, G. L. Woods, R. N. Jones, J. T. Kirby, M. L. Beach, D. J. Biedenbach, M. A. Pfaller, and D. M. Livermore. 2004. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48:4606-4610.
31. Paramythiotou, E., J. C. Lucet, J. F. Timsit, D. Vanjak, C. Paugam-Burtz, J. L. Trouillet, S. Belloc, N. Kassis, A. Karabinis, and A. Andremont. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677.
32. Philippe, E., M. Weiss, J. M. Shultz, F. Yeomans, and N. J. Ehrenkranz. 1999. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin. Perform. Qual. Health Care 7:83-87.
33. Pugh, R. N., I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:646-649.
34. Spiegelman, D., and E. Hertzmark. 2005. Easy SAS calculations for risk or prevalence ratios and differences. Am. J. Epidemiol. 162:199-200.
35. Tacconelli, E., M. Tumbarello, S. Bertagnolio, R. Citton, T. Spanu, G. Fadda, and R. Cauda. 2002. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg. Infect. Dis. 8:220-221.
36. Zhang, H., and S. Burthon. 1999. Recursive partitioning in the health sciences. Springer, New York, N.Y.